公开(公告)号：US20240343796A1

公开(公告)日：2024-10-17

申请号：US18528157

申请日：2023-12-04

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo Attar ,  Francois Gaudet ,  Mark Tornetta ,  Alexey Teplyakov ,  Mark Mendonca ,  Suzanne Edavettal ,  Kodandaram Pillarisetti ,  Nathan Majewski ,  Yingzhe Li ,  Leopoldo L. Luistro, III ,  Diana Chin

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K39/0011 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.

公开(公告)号：US11884722B2

公开(公告)日：2024-01-30

申请号：US18157800

申请日：2023-01-20

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo Attar ,  Francois Gaudet ,  Mark Tornetta ,  Alexey Teplyakov ,  Mark Mendonca ,  Suzanne Edavettal ,  Kodandaram Pillarisetti ,  Nathan Majewski ,  Yingzhe Li ,  Leopoldo L. Luistro, III ,  Diana Chin

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K39/0011 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.